Zacks Investment Research on MSN
GSK out-licenses rights for rare liver disease drug to Alfasigma
GSK plc GSK signed a license agreement with Italy-based Alfasigma. Per the terms of the agreement, Alfasigma has acquired exclusive global rights from GSK to develop and market linerixibat, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results